Early access to medicines, adaptive licensing and a new 'breakthrough' designation - UK expert group wish list
This article was originally published in SRA
Executive Summary
A group of experts has called on the UK regulator, the MHRA, to sort out funding issues regarding its proposed early access to medicines scheme and to get the project up and running as soon as possible1,2. It also urges the European Medicines Agency to make progress on its delayed adaptive licensing project, and calls for a designation similar to the breakthrough therapy status that was recently introduced in the US.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.